Novo Health Care Service and Encore Surgical Supplies have unveiled HealPACK, an innovative surgical dressing solution ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care.

Recent research into bacterial cellulose patches may speed plants' recovery, improve grafting and help with preservation.

Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

The South Carolina Burn Center at the Medical University of South Carolina and The Zucker Institute for Innovation ...

You're invited to publicize your 2024–2025 new product introductions in LCGC International. For our 2025 review, you may submit any product launched between May 2024 and March 2025. We have four forms ...

While the world might see addiction as a series of destructive choices, those battling substance use know it's often a ...